Xidorin Tablet contains Midodrine 2.5 mg, an alpha-1 adrenergic agonist indicated for the treatment of symptomatic orthostatic hypotension. Midodrine acts by constricting arterioles and veins, thereby increasing peripheral vascular resistance and elevating blood pressure. This pharmacological action helps alleviate symptoms such as dizziness, lightheadedness, and syncope associated with low blood pressure upon standing. Xidorin is typically prescribed for patients who experience significant drops in blood pressure due to autonomic dysfunction or other underlying causes. The tablet should be administered orally, with dosing individualized based on clinical response and tolerability. Common adverse effects may include piloerection, pruritus, urinary retention, and supine hypertension; therefore, blood pressure monitoring in both supine and standing positions is recommended during therapy. Caution is advised in patients with severe cardiac disease, renal impairment, or urinary retention. Xidorin should not be used in patients with pheochromocytoma or thyrotoxicosis. Concomitant use with other vasopressors or antihypertensive agents requires careful consideration to avoid adverse hemodynamic interactions. Overall, Xidorin Tablet offers an effective therapeutic option for managing orthostatic hypotension, improving patient quality of life by reducing symptomatic hypotension episodes.